We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+55.52%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
+$444M
Cap. Flow %
6.3%
Top 10 Hldgs %
74.64%
Holding
54
New
9
Increased
21
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$143M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$114M
3
PMVP icon
PMV Pharmaceuticals
PMVP
+$68.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$58.6M
5
ALT icon
Altimmune
ALT
+$40M

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$48.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$33.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.1M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 66.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$40.9M 0.58%
7,250,000
+150,000
+2% +$715K
ATNX
27
DELISTED
Athenex, Inc. Common Stock
ATNX
$39.5M 0.56%
163,250
-29,250
-15% -$7.02M
MRNS
28
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$38.5M 0.55%
3,000,000
+10,000
+0.3% +$86.3K
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.12B
$31M 0.44%
2,800,000
– –
CUE icon
30
Cue Biopharma
CUE
$114M
$28.1M 0.4%
62,333
– –
ALT icon
31
Altimmune
ALT
$599M
$26.4M 0.38%
+2,000,000
New +$40M
AMRN
32
Amarin Corp
AMRN
$303M
$25.3M 0.36%
300,000
+200,000
+200% +$24M
TVTX icon
33
Travere Therapeutics
TVTX
$5.78B
$24.5M 0.35%
1,325,000
+275,000
+26% +$5.35M
RLAY icon
34
Relay Therapeutics
RLAY
$4.31B
$21.3M 0.3%
+500,000
New +$19.1M
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
$21.2M 0.3%
4,200,000
-365,655
-8% -$2.66M
RAPT
36
DELISTED
RAPT Therapeutics
RAPT
$18.5M 0.26%
+71,875
New +$16M
BDTX icon
37
Black Diamond Therapeutics
BDTX
$112M
$18.2M 0.26%
602,500
+77,500
+15% +$2.36M
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
$15.7M 0.22%
875,000
-1,375,000
-61% -$33.7M
RNAM
39
DELISTED
Avidity Biosciences
RNAM
$15.3M 0.22%
545,000
-40,000
-7% -$1.16M
PNT
40
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$14.4M 0.2%
+1,000,000
New +$13.6M
GNCA
41
DELISTED
Genocea Biosciences, Inc.
GNCA
$11.6M 0.17%
+5,084,184
New +$13.3M
ITOS
42
DELISTED
iTeos Therapeutics
ITOS
$11.3M 0.16%
+460,000
New +$12.4M
FENC icon
43
Fennec Pharmaceuticals
FENC
$402M
$10.1M 0.14%
1,670,000
– –
TNGX icon
44
Tango Therapeutics
TNGX
$4.41B
$8.67M 0.12%
+800,000
New +$8.17M
ALIM
45
DELISTED
Alimera Sciences
ALIM
$2.02M 0.03%
415,999
– –
KYMR icon
46
Kymera Therapeutics
KYMR
$8.94B
$1.6M 0.02%
+49,400
New +$1.51M
ADAP
47
CALL
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-200,000
Closed -$70K
ALLO icon
48
Allogene Therapeutics
ALLO
$694M
– –
-1,128,594
Closed -$48.3M
AUPH icon
49
Aurinia Pharmaceuticals
AUPH
$2.04B
– –
-1,670,000
Closed -$27.1M
CRDF icon
50
Cardiff Oncology
CRDF
$77.2M
– –
-1,000,000
Closed -$5.01M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Avoro Capital Advisors held 54 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Avoro Capital Advisors deployed $444M of net new capital in Q3 2020, opening 9 new positions and adding to 21 existing holdings. Its largest new stake was PMV Pharmaceuticals: 1,850,000 shares worth $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Zogenix, Inc., an estimated $33.7M trimmed.

  • Avoro Capital Advisors's largest Q3 2020 buy was PMV Pharmaceuticals: 1,850,000 shares worth $57.6M.
  • Avoro Capital Advisors added most to Arena Pharmaceuticals Inc in Q3 2020, an estimated $143M increase.
  • Avoro Capital Advisors's biggest Q3 2020 reduction was Zogenix, Inc., cutting an estimated $33.7M.
  • Avoro Capital Advisors fully exited Allogene Therapeutics in Q3 2020, selling an estimated $48.3M.
  • Avoro Capital Advisors's ten largest holdings make up 75% of its $7.04B portfolio in Q3 2020.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q3 2020.
  • Avoro Capital Advisors's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Avoro Capital Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.